Also known as hyperglycemic factor and hyperglycemic-glycogenolytic factor.
At 80 weeks retatrutide lowered A1C by 2.2% and reduced weight ~20% (44–47 lbs) versus Ozempic 2 mg’s 1.8% A1C reduction and 9.4% (~21 lbs) weight loss.
Oral orforglipron showed 5–11% weight loss at 72 weeks and 1.2–1.9 percentage‑point HbA1c reductions; CHMP opinion now goes to the European Commission for an EU licence.
Triple agonist produced up to 20.8% weight loss and up to 1.6% A1C reduction at 80 weeks in adults with type 2 diabetes and obesity.
First‑in‑class triple agonist delivered large 80‑week weight losses and meaningful A1C and cardiometabolic improvements in difficult‑to‑treat obesity populations.
Phase III data show targeted visceral and liver fat reductions with minimal lean mass loss and sustained weight loss in obesity and MASLD populations.
Phase 3 TRIUMPH-1: three doses met endpoints at 80 weeks with dose-related, substantial weight loss. 104-week extension in BMI≥35 showed further loss; cardiometabolic markers improved; GI AEs common.
